Equities

Endexx Corp

EDXC:PKL

Endexx Corp

Actions
  • Price (USD)0.0185
  • Today's Change0.001 / 2.78%
  • Shares traded17.00k
  • 1 Year change-61.05%
  • Beta-0.1001
Data delayed at least 15 minutes, as of May 28 2024 19:22 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Endexx Corporation develops hemp-derived, cannabidiol (CBD)-based products, each formulated to address key segments of the health and wellness market. Through its subsidiaries, the Company sells oils, extracts, topicals, and pet products, all with the shared purpose of supporting the therapeutic relief of pain and inflammation for humans and pets through its e-commerce site www.cbdunlimited.com, as well as other online and in-store retailers. In addition to its consumer products, the Company's Gorilla-Tek division offers an automated dispensing system providing a secure method of distributing hemp-based products. The Company also owns and operates a number of subsidiaries that offer technology and consulting solutions to the hemp and hemp-derived product industry, including Seed-to-Shelf compliance and inventory tracking and process management system for regulated products in a front of counter pharmacy support platform.

  • Revenue in USD (TTM)4.64m
  • Net income in USD6.93m
  • Incorporated1997
  • Employees--
  • Location
    Endexx Corp38246 North Hazelwood CircleCAVE CREEK 85331United StatesUSA
  • Phone+1 (480) 595-6900
  • Fax+1 (480) 626-1696
  • Websitehttps://endexx.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Energy Finders Inc4.06m-2.92m8.61m46.00------2.12-0.272-0.2721.523.04------88,304.35--------27.45---71.79--0.6706-12.570.564--------------
Paranovus Entertainment Technology Ltd51.46m-42.62m8.69m80.00--0.8143--0.169-7.16-7.499.891.461.1859.614.15643,209.90-91.12-23.19-119.36-27.214.9223.09-77.15-24.253.97-2,465.220.00--9.689.80-45.84---21.93--
BioRestorative Therapies Inc145.80k-14.42m8.73m11.00--0.5264--59.90-3.54-3.540.03462.450.01--8.2613,254.55-99.26-199.86-104.68-334.04-----9,887.16-19,887.03----0.00--21.705.6122.06--67.77--
BioNexus Gene Lab Corp9.78m-2.66m9.19m30.00--0.983--0.9396-0.14-0.140.6510.52891.018.555.80---27.53-3.83-33.16-5.0213.5614.55-27.25-3.043.98-162.450.00---10.60115.07-638.56--30.40--
Weed Inc0.00-5.19k9.27m2.00--86.24236.69---0.00001-0.000010.000.00090.00----0.00-0.4942-385.93-9.56-822.37-----------23.030.5461------97.93---59.13--
Pacific Software Inc0.00-77.46k9.36m0.00--0.3008-----0.1832-0.18320.000.76460.00-------26.19-620.48-66.38-------------6.290.00-------13.29------
Endexx Corp4.64m6.93m9.37m--1.39--1.582.020.01330.01330.0091-0.02550.67734.3713.54--86.51------28.73--127.74--0.0664------228.66--28.26------
CV Sciences Inc15.86m-3.23m9.47m42.00--4.01--0.597-0.0207-0.02070.10120.01451.591.4227.25377,571.40-32.43-43.42-83.71-77.7545.1351.81-20.38-45.680.2677-13.320.0472---1.24-19.80133.96-20.87----
Oragenics Inc20.63k-20.26m9.50m5.00--9.20--460.45-7.98-7.980.00790.58590.0026----4,126.00-258.71-97.60-312.34-106.24-----98,214.93-36,169.75----0.0461---71.37---44.56--51.64--
BioCardia Inc468.00k-10.34m9.56m16.00------20.42-0.4692-0.46920.0209-0.08480.0954--4.4429,250.00-210.81-107.34-1,190.90-154.17-----2,208.76-1,779.24---------64.72-5.262.82---28.89--
Enzon Pharmaceuticals Inc0.00221.00k9.73m0.0044.012.95----0.0030.0030.000.6240.00------3.21-0.86543.24-0.8851-------159.43----0.00---100.00--106.71-55.86----
Coeptis Therapeutics Holdings Inc0.00-16.31m9.87m5.00--2.22-----0.5804-0.58040.000.11970.00----0.00-212.70-36.90-378.58-37.81------------0.349------43.40------
Universe Pharmaceuticals Inc32.31m-6.16m10.03m225.00--0.2522--0.3103-1.70-1.708.9110.910.57277.932.50143,594.40-10.925.31-14.347.0731.9346.26-19.086.252.43-28.050.12180.00-19.522.5329.46---21.17--
ABVC Biopharma Inc25.37k-12.62m10.04m16.00--1.27--395.70-2.37-2.370.00430.72840.002--0.06731,585.63-103.15-103.38-189.31-231.54-854.2076.25-51,218.29-2,019.89---3.190.1853---84.2885.3935.97------
Allarity Therapeutics Inc0.00-20.94m10.13m5.00---------599.34-599.340.00-18.880.00----0.00-100.46--------------------------3.02------
Data as of May 28 2024. Currency figures normalised to Endexx Corp's reporting currency: US Dollar USD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.